We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · June 17, 2020

Patiromer in the Heart Failure Subgroup of the AMBER Trial

European Journal of Heart Failure

 

Additional Info

European Journal of Heart Failure
Patiromer Versus Placebo to Enable Spironolactone Use in Patients With Resistant Hypertension and Chronic Kidney Disease (AMBER): Results in the Pre-Specified Subgroup With Heart Failure
Eur. J. Heart Fail 2020 May 25;[EPub Ahead of Print], P Rossignol, B Williams, MR Mayo, S Warren, S Arthur, G Ackourey, WB White, R Agarwal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading